Chronic Myeloid Leukemia

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia

Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia

By

Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Time of Response to TKI Therapies May Influence Patient Outcomes in CML

Time of Response to TKI Therapies May Influence Patient Outcomes in CML

By

Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.

Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML

Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML

By

There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.

The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving

The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving

By

Perspectives differ on whether ponatinib is a niche drug that should be reserved for younger patients.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

By

A large, long-term study found a 97% event-free survival rate at 18 months.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

By

For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

By

Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

By

Nearly half of patients with CML who achieved a deep molecular response following treatment with nilotinib remained in remission for 96 weeks.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

By

Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

By

Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

By

There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Pediatric CML: Life-Long Considerations With TKI Therapy

Pediatric CML: Life-Long Considerations With TKI Therapy

By

Because most patients with CML are adults, there are no established treatment guidelines and many clinicians apply adult guidelines to their pediatric patients.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

By

Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid leukemia.

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia

By

Targeted therapies among patients with chronic myeloid leukemia have improved over time, leading to patients achieving high rates of deep molecular response — a prerequisite criteria for tyrosine kinase inhibitor discontinuation.

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia

By

Dasatinib 100 mg is currently approved for chronic myeloid leukemia but has been associated with high rates of adverse events.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Leukemia Treatment Regimens: Chronic Myeloid Leukemia (CML)

View detailed treatment regimens for chronic myeloid leukemia (CML), with detailed instructions about primary treatment and follow-up treatment.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs